Pacira Pharmaceuticals, Inc. Reports Third Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Pacira Pharmaceuticals (PCRX) PT Raised to $46 at Mizuho Securities Following 3Q
November 5, 2018 7:16 AM ESTMizuho Securities analyst Irina Koffler raised the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $46.00 (from $43.00) while maintaining a Neutral rating following the company's 3Q earnings report. Mizuho Securities raised 2018 Exparel sales to $331.8M (from $321.2M) and 2019 estimates to $396.5M (from $376.8M prior); both above... More
Pacira Pharmaceuticals (PCRX) PT Raised to $60 at RBC Capital
November 2, 2018 7:14 AM EDTRBC Capital analyst Randall Stanicky raised the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $60.00 (from $55.00) while maintaining a Outperform rating.
... MorePacira Pharmaceuticals (PCRX) PT Raised to $55 at Piper Jaffray
November 1, 2018 1:13 PM EDTPiper Jaffray analyst David Amsellem raised the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $55.00 (from $51.00) while maintaining a Overweight rating.
Amsellem cited a clear uptick in Exparel sales growth.
... MoreUPDATE: Pacira Pharma (PCRX) Tops Q3 EPS by 23c, Revenues Beat; Boosts FY18 Revenue Outlook
November 1, 2018 8:13 AM EDT(Updated - November 1, 2018 8:13 AM EDT)
Pacira Pharma (NASDAQ: PCRX) reported Q3 EPS of $0.31, $0.23 better than the analyst estimate of $0.08. Revenue for the quarter came in at $82.2 million versus the consensus estimate of $80.18 million.
EXPAREL net product sales were $82.2 million in the third quarter of 2018, a 23% increase over the $66.8 million reported for the third quarter of 2017.Total operating expenses were $79.4 million in the third quarter of 2018, compared to $70.9 million in the third quarter of 2017.GAAP net loss was $0.6 million, or $(0.02) per share (basic and diluted), in the third... More